Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» obesity
obesity
Weight-loss market to see 16 new drugs by 2029, report estimates
Reuters
Tue, 09/10/24 - 04:29 pm
weight loss
obesity
Amgen
Pfizer
Roche
Novo Nordisk
Eli Lilly
Boehinger Ingelheim
Structure Therapeutics
Viking Therapeutics
Zealand Pharma
Altimmune
Terns Pharmaceuticals' oral obesity drug shows promise in early study, shares jump
Reuters
Mon, 09/9/24 - 11:29 am
Terns Pharmaceuticals
obesity
clinical trials
OrsoBio Announces Oversubscribed $67 Million Series B Financing to Accelerate Mitochondrial Protonophore Portfolio Targeting Obesity and Associated Disorders
Businesswire
Fri, 09/6/24 - 10:50 am
OrsoBio
obesity
funding
57 Million Eligible For GLP-1 Drug Coverage In U.S. And That’s Just Those Under 65
Forbes
Thu, 09/5/24 - 10:29 pm
obesity
GLP-1
Novo Nordisk
Eli Lilly
Ozempic
Wegovy
insurers
Amgen Plans Phase III Program for Next-Gen Obesity Drug Targeting Liver and Kidney Diseases
BioSpace
Thu, 09/5/24 - 11:40 am
Amgen
obesity
MariTide
Medicare
BioAge files for IPO, plans pair of midstage obesity trials
Fierce Biotech
Wed, 09/4/24 - 11:40 am
BioAge Labs
IPOs
Eli Lilly
obesity
clinical trials
Eli Lilly bets $1B in biobucks on Haya to scour dark genome for obesity targets
Fierce Biotech
Wed, 09/4/24 - 11:37 am
Eli Lilly
Haya Therapeutics
dark genome
obesity
drug discovery
New research could ease concerns over suicide risk of obesity drugs
BioPharma Dive
Tue, 09/3/24 - 05:58 pm
obesity
suicide
GLP-1
Novo Nordisk
Eli Lilly
Ozempic
Wegovy
Mounjaro
Zepbound
Novo builds heart failure case for semaglutide
BioPharma Dive
Fri, 08/30/24 - 11:31 am
Novo Nordisk
obesity
semaglutide
cardiovascular disease
Ambrosia lands $16m to ‘improve on existing GLP-1 drugs’
Longevity Technology
Wed, 08/21/24 - 11:26 am
Ambrosia Biosciences
funding
GLP-1 agonists
obesity
Pfizer
Array Biopharma
Forget Mounjaro: Eli Lilly's Next Big Blockbuster Has Arrived
Motley Fool
Sun, 08/18/24 - 09:19 pm
Eli Lilly
FDA
obesity
Zepbound
After clearing out heart disease drug, Arrowhead maps out obesity development plans
Fierce Biotech
Wed, 08/14/24 - 10:41 pm
Arrowhead Pharmaceuticals
RNAi
R&D
obesity
heart disease
5 Obesity Readouts to Watch in the Second Half of 2024
BioSpace
Tue, 08/13/24 - 11:47 am
obesity
clinical trials
Novo Nordisk
CagriSema
Amgen
MariTide
Monlunabant
Aphaia Pharma
APHD-012
Terns Pharmaceuticals
TERN-601
Novo Nordisk pulls its FDA heart failure submission for Wegovy, will reapply early next year
Fierce Pharma
Wed, 08/7/24 - 11:47 am
Novo Nordisk
heart failure
obesity
Wegovy
FDA
Here's What AstraZeneca's CEO Has to Say About the Weight Loss Drugs Market
Motley Fool
Sun, 08/4/24 - 06:30 pm
AstraZeneca
Pharma CEOs
weight loss
obesity
Pascal Soriot
Pfizer’s Bourla confident in company’s obesity drug position, despite delays
Pharma Voice
Thu, 08/1/24 - 11:14 am
Pfizer
Pharma CEOs
Albert Bourla
obesity
GLP-1 drugs are driving up healthcare costs
Medical Marketing and Media
Fri, 07/26/24 - 11:03 am
obesity
weight loss
GLP-1 agonist
healthcare costs
Eli Lily
Novo Nordisk
Wegovy
Zepbound
Roche says it’ll move quickly with ‘differentiated’ obesity drugs
BioPharma Dive
Thu, 07/25/24 - 10:05 pm
Roche
obesity
Carmot Therapeutics
CT-388
CT-996
Viking shares jump on plans to speed obesity drug into late-stage testing
BioPharma Dive
Thu, 07/25/24 - 11:23 am
Viking Therapeutics
obesity
clinical trials
VK2735
Novo Nordisk's Wegovy gets UK approval for lowering heart risks
Reuters
Tue, 07/23/24 - 11:24 am
Novo Nordisk
UK
Wegovy
heart disease
stroke
obesity
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »